Commentary: Adjuvant mitotane for adrenocortical cancer - A recurring controversy

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 10, 2008, Pages 3730-3732

  Huang, Hui ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADRENAL CORTEX CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR REGRESSION; ADJUVANT CHEMOTHERAPY; ADRENAL CORTEX TUMOR; CARCINOMA; DOSE RESPONSE; METASTASIS; PATHOLOGY; RECURRENT DISEASE;

ADRENAL CORTEX NEOPLASMS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MITOTANE; NEOPLASM METASTASIS; RECURRENCE;

EID: 53749104093     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0579     Document Type: Note

References (10)

1. Young RB, Bryson MJ, Sweat ML, Street JC 1973 Complexing of DDT and o,p′DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem 4:585-591
2. Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC 1978 o,p′-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer 42:2177-2181
3. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A 2007 Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372-2380
4. Bertherat J, Coste J, Bertagna X 2007 Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med 357:1256-1257; author reply 1259
5. Bergenstal D, Hertz R, Lipsett M, Moy R 1960 Chemotherapy of adrenocortical cancer with o,p′ DDD. Ann Intern Med 53:672-682
6. Hutter Jr AM, Kayhoe DE 1966 Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 41:572-580
7. Lubitz JA, Freeman L, Okun R 1973 Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223:1109-1112
8. Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L, Angeli A 2000 Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 85:2234-2238
9. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M 2001 Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385-1392
10. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D 1984 The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47-53